Eli Lilly CEO: The Weight-Loss Drug Revolutio...

Who gets access to capital, and who gets left out? Nicolai Tangen talks with financier and philanthropist Mike Milken, a pioneer of the high-yield bond market, to trace how a chance encounter at 19 shaped a lifelong mission to widen access to capital. They discuss why the “safest ...  Show more

On this week’s Friday Wrap-Up, Marthe Skaar catches up with Nicolai Tangen, joining from New York, to break down his podcast conversation with John Ketchum, CEO of NextEra Energy. They discuss how AI is driving a surge in demand for power, why nuclear and batteries are becoming m ...  Show more

Eli Lilly is the world's most valuable drug company, known for its blockbuster anti-obesity drugs that's transforming America. In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see ...  Show more

(0:00) Introducing Eli Lilly CEO Dave Ricks

(1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China

(7:08) GLP-1 pricing and capital allocation after a breakout pharma product

(12:56) Why Biotech VC has plummeted, " ...

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more